Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Tobias Raphael Overbeck1,2, Annika Reiffert3, Katja Schmitz3,4

  • 1Department of Hematology and Medical Oncology, University Medical Center Göttingen, 37075 Göttingen, Germany.

Cancers
|June 10, 2023
PubMed
概括
此摘要是机器生成的。

神经缩型氨酸激酶 (NTRK) 融合在非小细胞肺癌 (NSCLC) 中很罕见,在不到1%的患者中发现. 免疫组织化学 (IHC) 随后的RNA-NGS是NTRK融合的一种可行的选方法.

关键词:
鱼类 鱼类 是一种鱼类.在NSCLCLC中,我们可以看到.俄罗斯国家广播电视台 (NTRK)基于RNA的下一代测序.光在现场混合化光.免疫组织化学 免疫组织化学肺癌是一种肺癌.有针对性的治疗.

相关实验视频

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Training on PD-L1 scoring in non-small cell lung cancer with high intra- and inter-reader agreement: results of a worldwide microscopic/digital image-based training of 751 pathologists.

British journal of biomedical science·2026
Same author

Correction: Comparison of real-world efficacy and safety of nivolumab plus ipilimumab or pembrolizumab combined with platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer in a German population.

Cancer immunology, immunotherapy : CII·2026
Same author

Influence of Structural Features of Peptides on Their Affinity to Cotton Linters Paper.

ACS omega·2026
Same author

Comparison of real-world efficacy and safety of nivolumab plus ipilimumab or pembrolizumab combined with platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer in a German population.

Cancer immunology, immunotherapy : CII·2026
Same author

How Should Primary Pulmonary Sarcoma be Staged? Results of an International Multicentre Analysis.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery·2026
Same author

Endothelial ZBTB16: a molecular shield against cardiac aging.

European heart journal·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
Same journal

Neoadjuvant Immunotherapy-Based Treatment Versus Chemotherapy Alone in Resectable Locally Advanced dMMR/MSI-H Gastric Cancer: A Real-World Study with Meta-Analysis.

Cancers·2026
查看所有相关文章

科学领域:

  • 在瘤学瘤学.
  • 分子诊断学 分子诊断
  • 遗传学 遗传学 是一个

背景情况:

  • 非小细胞肺癌 (NSCLC) 的诊断依赖于识别可操作的分子变化.
  • 神经缩型氨酸激酶 (NTRK) 融合是NSCLC中罕见但可向的遗传改变.
  • 目前NSCLC的诊断途径可能无法最佳地检测NTRK融合.

研究的目的:

  • 为了确定在常规NSCLC诊断环境中NTRK融合的流行率.
  • 评估查策略的可行性,包括免疫组织化学 (IHC),光在位杂交 (FISH) 和基于RNA的下一代测序 (RNA-NGS).

主要方法:

  • 选了1068名使用IHC,其次是RNA-NGS (n=973) 或直接FISH (n=95) 的NSCLC患者.
  • 研究了NTRK融合及其与其他常见NSCLC驱动突变 (EGFR,ALK,ROS1,BRAF,RET,KRAS) 的同时发生.

主要成果:

  • 在0.2%未被选择的NSCLC患者中 (2/1068) 发现了NTRK融合.
  • 免疫组织化学 (IHC) 确定了14.8%的患者呈阳性,随后的RNA-NGS在排除其他变化后,在30.5%的IHC阳性病例中确认了NTRK融合.
  • 与EGFR,ALK,ROS1,BRAF,RET和KRAS变异的NTRK融合是相互排斥的.

结论:

  • NTRK融合阳性NSCLC很少见,占所有NSCLC病例的不到1%.
  • 在临床实践中,RNA-NGS和FISH是检测NTRK融合的可靠方法.
  • 建议采用包含泛Trk IHC,其次是RNA-NGS的诊断工作流程,可能排除具有并发常见突变的患者以改进检测.